Jefferies Financial Group Boosts Stake in Embecta Corp.

Institutional investor increases position in medical device company by over 40%.

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Jefferies Financial Group Inc. has increased its holdings in Embecta Corp. (NASDAQ:EMBC) by 40.4% in the third quarter, according to a recent 13F filing with the SEC. The firm now owns 1,884,875 shares of the medical device company's stock, representing a 3.22% ownership stake valued at $26.6 million.

Why it matters

Jefferies' increased investment in Embecta signals confidence in the company's growth prospects as a pure-play diabetes care business following its spinoff from Becton, Dickinson and Company in 2021. Embecta focuses exclusively on insulin delivery and blood glucose monitoring products, which are seeing rising demand amid the global diabetes epidemic.

The details

According to the 13F filing, Jefferies Financial Group purchased an additional 542,162 shares of Embecta during the third quarter. The investment firm is now one of Embecta's largest institutional shareholders, owning nearly 3.2% of the company's outstanding stock.

  • Jefferies Financial Group increased its Embecta holdings in the third quarter of 2026.
  • Embecta was spun off from Becton, Dickinson and Company on July 1, 2021.

The players

Jefferies Financial Group Inc.

A diversified financial services company that provides investment banking, capital markets, and wealth management services.

Embecta Corp.

A medical device company focused exclusively on the development, manufacturing, and commercialization of products for insulin delivery and blood glucose monitoring for people with diabetes.

Got photos? Submit your photos here. ›

The takeaway

Jefferies' increased stake in Embecta suggests the investment firm sees strong growth potential in the company's specialized diabetes care product portfolio as the global diabetes population continues to rise. This vote of confidence from a major institutional investor could signal positive momentum for Embecta as it establishes itself as an independent public company.